FluPep - Peptide-based therapy of influenza virus infection

submit enquiry
Influenza virus (c) Shutterstock
Influenza virus (c) Shutterstock

University: University of Edinburgh

Sector(s): Healthcare & Pharmaceuticals, Life Sciences

About Opportunity:

This anti-influenza therapy offers potential as anti-viral treatment as well as prevention against all major flu strains, including influenza A infection.

Broad-spectrum anti-influenza peptides have been developed to treat and prevent flu and a wider range of clinically relevant viral infections. These peptides have a novel mechanism of action, making them less likely to induce viral resistance and very effective at combatting flu.

Current anti-influenza therapy options are also restricted in efficacy by rapid viral evolution and subsequent drug resistance. Over 80% of currently circulating influenza strains are already resistant to the market leading anti-viral.

University of Edinburgh researchers have peptides that block entry of the influenza virus into the cells they would normally infect. This mode of action differentiates the technology from currently available therapies and, in doing so, facilitates potential as a combination therapy (as well as a monotherapy) and minimises, the risk of target viruses developing resistance. In a mouse model of influenza infection, viral titres were 4 logs lower in mice treated with the leading peptide compared to no treatment. In vivo and in vitro toxicological and safety studies have also been carried out.

Key Benefits:

  • Scope to treat as well as prevent flu – effective in mice even days after infection
  • Broad spectrum effect against all major flu strains, including H1,H3 and H5 strains
  • Effective when delivered intra-nasally – capable of preventing influenza A infection delivered directly to the lung in vivo
  • Safe to use with low toxicity and immunogenicity
  • Small peptide facilitating manufacture and mindful of cost
  • Mechanism of action which hinders resistance


  • Prevention and treatment of influenza

IP Status:

This technology is available to access under the University's Open Technology initiative.

Documentation describing the technology and invention (Follow-up information pack, copy of the published patent at PCT stage) will be provided following acceptance of the University's Open Technology standard terms and conditions.

It would help speed up access to this technology if you confirm acceptance of the published terms and conditions in the enquiry form below, indicating your proposed use for this technology.


Please enter your name.

Please enter the name of the company you work for.

Is your company an SME?

Please select the country you are in.

Please select what part of the UK you are in.

Please select from the following options.

Please enter your email address.

To help us process your enquiry faster please enter some details about the information you are interested in.

Words remaining:

Related Opportunities

  • Telomerase Promoter - Cancer Therapies

    The University of Glasgow has developed a (Ad-hTR-NTR) which has been extensively tested on Ovarian cancer cells.

    Expires: Created:
  • SNP-based assay for analysis of MRSA

    This assay is a rapid and reproducible approach for epidemiological analysis of methicillin-resistant Staphylococcus aureus (MRSA) clinical isolates. The assay identifies different strains on EMRSA-15, which is a major cause of hospital acquired MRSA infections in the UK and in other parts of the wo...

    Expires: Created:
  • Catanostics - Non-Invasive Early Stage Cataract Diagnosis & Severity Quantification tool

    Catanostics (Cataract Diagnostics) offers an alternative to the slit lamp currently used for cataract diagnosis before referring a patient for cataract surgery. Our non-invasive fluorescence scan offers "better diagnosis" through non-subjective analysis of data on cataract symptoms & severity lea...

    Expires: Created:
  • Transforming Pharmaceutical Crystal Forms

    The innovation provides a gas-induced method for phase-transforming organic solids, such as pharmaceutical crystals. The inventive method subjects the polymorphs of pharmaceutical agents to various pressures of gases (such as CO2, N2O, and CH4) to induce phase transform with ease.

    Expires: Created:
  • Sperm Motility Enhancers for Assisted Reproductive Technology

    Sperm Motility Enhancers: A Novel Strategy for Assisted Reproductive Technology (ART) based on the direct relationship between human fertility and sperm motility,the University of Dundee has successfully identified FDA-approved compounds with robust and effective stimulation on patient sperm motilit...

    Expires: Created:

Alerts Signup

Sign up to our technology alerts and be the first to hear about any new technology opportunities from Scotland's universities

Register Now for University Technology.com Alerts

Search Filter

Share this page

Use the buttons below to share these technology opportunities on your favourite social networking site. You can also share them from inside the individual opportunity.